Myocardial infarctions, more commonly known as heart attacks, generally occur when a thrombus (a clot, or an aggregate of debris, red blood cells, and platelets trapped in a network of fibrin protein) creates an arterial obstruction due to atherosclerotic plaque. The resulting severe ischemia (low or absent blood flow) sets up a serious supply deficit for the very metabolically active heart tissues. Beginning about 20 minutes into ischemia, a wave of cellular death rolls through the now stagnant perfusion field, from the innermost cardiac layers toward the outermost. Over the ensuing three to six hours, cell death is profound, with cardiac muscle cells, vascular cells, resident fibroblasts, and nerve cells all affected. There is a prototypical sequence of events related to a myocardial infarction:
Anoxia – When the occlusion occurs, blood flow is reduced significantly. If the ischemia is profound enough, there will be a functional absence of oxygen availability, or anoxia. The shorter the period of anoxia, the less damage to the cardiac tissues. Within 20 minutes of anoxia, permanent damage has begun.
Necrosis – If the period of anoxia is extended beyond a cell’s reserve capacity, cell death results. Exhaustion of available aerobic and anaerobic metabolic substrates, increased toxicity from failed removal of cellular wastes, and more make cellular survival impossible. The duration of this stage begins at about 20 minutes post-blockage and can continue for about six hours, at which time all at-risk cells in the perfusion field will have succumbed.
Granulation – Neutrophils and then macrophages (two cell types that contribute to the body’s immune system) infiltrate the infarcted tissues at around four to 12 hours post-event. Neutrophils and macrophages engulf and remove the degrading dead cells. This prepares the region for subsequent remodeling that will replace cells and tissue architecture. At the same time, fibroblasts from within the infarcted zone and from unaffected proximal areas migrate to the necrotic zone and begin proliferating and secreting fibronectin, a type of loose connective tissue protein. The activities of these cell types — removing necrosis, adding fibronectin, and other activities that are precursors to scarring — remodels the infarcted tissue, which takes on a roughly granular appearance. Hence the name of this stage.
Scarring – The same cells active in granulation remain so for quite some time. For approximately two months after the infarction event, a robust scar tissue will develop, replacing the once viable and contractile cardiac tissues. The scar is largely a function of fibroblast cells altering their production, exuding less fibronectin and adding much more collagen into the extracellular spaces and matrices.
This sequence of processes profoundly affects the heart’s morphology beyond the localized cellular changes. The walls of the ventricles, the most common sites of infarction, are thickly muscled and replete with conductive cells driving the heartbeat. As we progress from time zero to the completion of scarring, dramatic changes occur in the shape, appearance, and function of the ventricles.
Myocardial infarction results in the thinning of the infarcted ventricle over time. As the wall thins, the chamber diameter inside increases. As remodeling and scarring occur, overall heart diameter also increases. This condition is known as pathological cardiac hypertrophy. The architectural changes increase mechanical stresses on the ventricular wall and a systematic decrease in contractile function. This means the ventricle is no longer able to contract with its full circumference; its contractions become asymmetrical. Cardiac output is significantly reduced due to scar-induced asymmetric contraction. The extent of functional loss after infarction is directly correlated to the amount of myocardium lost and scarred.
The sequence of events that follows a complete occlusion differs from that of an incomplete occlusion:
Complete occlusion → Anoxia → Necrosis → Granulation → Scarring & Impaired function
Incomplete occlusion → Hypoxia → Angiogenesis & Preserved function
Note that hypoxia — low but not absent oxygen availability — drives the formation of new capillaries and vessels within the margins of the affected perfusion field. The new vessels are driven to form from vessels higher in the perfusion field or from vessels in closely bordering perfusion fields. These additional small vessels supply blood to the hypoxic perfusion field, keeping some of the affected cardiac tissues viable and functioning normally. These new sets of vessels are called collateral vessels. They are similar to alternative routes around a traffic jam.
The effects of hypoxia on cardiac vessel angiogenesis is quite interesting. If we can create hypoxia in a normally functioning heart, we might be able to drive angiogenesis and expand the number of vessels delivering blood to all the heart’s tissues. This would create an infarction-resistant heart.
How could one induce and titrate the dose of cardiac hypoxia needed to drive angiogenesis? Exercise. Low doses of exercise have been demonstrated to enhance collateralization in both healthy and diseased hearts. One can conjecture that programmed and regular higher intensity exercise that pushes an athlete into more profound and transient systemic hypoxia may be effective in driving collateral growth and protecting the heart from future damage. While we can assemble a strong data-driven argument to support this conjecture, most research in this area is performed on ponies, pigs, and rats, who generally don’t or won’t do CrossFit in the laboratory.
Additional Reading
- The Heart, Part 1: Location & Orientation
- The Heart, Part 2: Muscular Organization
- The Heart, Part 3: Muscular Composition & Arrangement
- The Heart, Part 4: Conductive Pathway
- The Heart, Part 5: Blood Flow
- The Heart, Part 6: Blood Vessel Basics
- The Heart, Part 7: Coronary Circulation
- The Heart, Part 8: Systemic and Pulmonary Circulation
- The Heart, Part 9: Blood
- The Heart, Part 10: Myocardial Infarction
The Heart, Part 11: Myocardial Remodeling and Salvage